CD4+ T Cells in High-Risk MDS Patients Bear an Aberrant STAT Signaling Biosignature
Eleftheria Lamprianidou(Democritus University of Thrace), Ιoannis Kotsianidis(Democritus University of Thrace), Athanasios Galanopoulos, Sotirios G. Papageorgiou(University General Hospital Attikon), Sofia Vakalopoulou(Aristotle University of Thessaloniki), Paraskevi Miltiades(Democritus University of Thrace), Theodoros P. Vassilakopoulos(National and Kapodistrian University of Athens), Evangelia Nakou(Democritus University of Thrace), Constantinos Tsatalas(Democritus University of Thrace), Vassilia Garypidou(Aristotle University of Thessaloniki), Emmanuil Spanoudakis(Democritus University of Thrace)
Cited by 1
Related Papers
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633
Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide
|Journal of Clinical Oncology|2007|279
Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)
|Leukemia & lymphoma/Leukemia and lymphoma|2006|160